Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents

Author(s): Sophia Junker*, Oliver Ebert and Robert Bartsch

Volume 19, Issue 3, 2023

Published on: 23 September, 2022

Page: [303 - 313] Pages: 11

DOI: 10.2174/1573397118666220829123713

Price: $65

conference banner
Abstract

Objective: To investigate injection site pain (ISP) and other injection site outcomes caused by biologics administered alongside citrate-free (CF) and citrate-containing (CC) formulations.

Methods: Electronic literature databases (Medline, Embase, and Cochrane Library) were systematically searched for clinical trials and observational studies reporting on injection site outcomes after subcutaneous administration of biologics. Studies with unknown excipient formulations were excluded. The primary outcome was ISP, and secondary outcomes included any other reported injection site reactions (ISRs). Meta-analysis approaches were used to aggregate evidence identified via the conducted systematic literature review.

Results: A total of two observational studies, two cross-over/sequential trials, and three head-tohead comparison trials directly comparing CF with CC biologics were identified, as well as seven placebo-controlled trials. Evidence from five of the seven direct comparison studies suggested reduced pain perception at the injection site when CF formulations were applied. Findings for other ISRs were balanced between both formulations, with slightly favorable results for preparations without citrate. A meta-analysis of placebo-controlled trials found no significant difference between arms with CF formulations and placebo regarding the proportion of patients experiencing ISP (OR 0.62, 95% CI 0.30-1.28).

Conclusion: Excipient formulations are rarely specified in studies assessing pain and other ISRs of subcutaneously administered biologics. The available data indicate that subcutaneous administration of biologic agents without citrate may be associated with lower pain perception outcomes compared with treatment using CC formulations. Importantly, ISP is influenced by many factors which may have affected the results. More research is needed to assess how formulation excipients influence ISRs.

Keywords: Biologics, citrate, excipient, formulation, injection site pain, injection site reaction.

« Previous Next »
[1]
Nathan JJ, Ramchandani M, Kaur P. Manufacturing of Biologics. In: Yamauchi PS, Ed. Biologic and Systemic Agents in Dermatology. Cham: Springer International Publishing 2018; pp. 101-10.
[http://dx.doi.org/10.1007/978-3-319-66884-0_12]
[2]
Kuek A, Hazleman BL, Ostör AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Postgrad Med J 2007; 83(978): 251-60.
[http://dx.doi.org/10.1136/pgmj.2006.052688]
[3]
Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-90.
[http://dx.doi.org/10.3748/wjg.v20.i29.9675]
[4]
Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci 2017; 18(11): 2297.
[http://dx.doi.org/10.3390/ijms18112297]
[5]
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68: 1-26.
[http://dx.doi.org/10.1002/acr.22783]
[6]
World Health Organization. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs), Annex 2, TRS No 1004. Technical Report, 2016.
[7]
Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017; 76(10): 1679-87.
[http://dx.doi.org/10.1136/annrheumdis-2016-210459]
[8]
Lamanna WC, Holzmann J, Cohen HP, et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther 2018; 18(4): 369-79.
[http://dx.doi.org/10.1080/14712598.2018.1421169]
[9]
Irvine DJ, Su X, Kwong B. Routes of Delivery for Biological Drug Products. In: Pharmaceutical Sciences Encyclopedia. Wiley 2013; pp. 1-48.
[http://dx.doi.org/10.1002/9780470571224.pse521]
[10]
Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30(12): 2563-71.
[PMID: 14719195]
[11]
Grace E, Goldblum O, Renda L, et al. Injection site reactions in the Federal Adverse Event Reporting System (FAERS) post-marketing database vary among biologics approved to treat moderate-to-severe psoriasis. Dermatol Ther 2020; 10(1): 99-106.
[http://dx.doi.org/10.1007/s13555-019-00341-2] [PMID: 31734937]
[12]
Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50(5): 1400-11.
[http://dx.doi.org/10.1002/art.20217] [PMID: 15146409]
[13]
Mease PJ. Adalimumab in the treatment of arthritis. Ther Clin Risk Manag 2007; 3(1): 133-48.
[http://dx.doi.org/10.2147/tcrm.2007.3.1.133] [PMID: 18360621]
[14]
van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63(5): 508-16.
[http://dx.doi.org/10.1136/ard.2003.013052]
[15]
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48(1): 35-45.
[http://dx.doi.org/10.1002/art.10697]
[16]
Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: A single-centre, randomized controlled trial. Diabetes Obes Metab 2014; 16(10): 971-6.
[http://dx.doi.org/10.1111/dom.12304]
[17]
Jaber A, Bozzato GB, Vedrine L, Prais WA, Berube J, Laurent PE. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis. BMC Neurol 2008; 8(1): 38.
[http://dx.doi.org/10.1186/1471-2377-8-38] [PMID: 18845005]
[18]
Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol 2006; 98(2): 218-21.
[http://dx.doi.org/10.1111/j.1742-7843.2006.pto_271.x] [PMID: 16445598]
[19]
Gely C, Marín L, Gordillo J, et al. N032 Impact of pain due to subcutaneous administration of a biological drug. J Crohn’s Colitis 2018; 12 (Suppl. 1): S582-3.
[http://dx.doi.org/10.1093/ecco-jcc/jjx180.1046]
[20]
Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
[21]
National Institute for Health and Care Excellence. Single technology appraisal: User guide for company evidence submission template. 2015. Available from: https://www.nice.org.uk/process/pmg24.
[22]
Tacconelli E. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Lancet Infect Dis 2010; 10: 226.
[23]
Martínez-Casanova J, Acin P, Carballo N, Gonzalez R, Navarrete Rouco E, Perez García C. 5PSQ-070 Influence of pathology in injection pain reduction with a new formulation of original adalimumab. Patient Safety and Quality Assurance. European J Hospital Pharm 2019; 26(Suppl. 1): A233.2-4.
[24]
Yoshida T, Otaki Y, Katsuyama N, Seki M, Kubota J. New adalimumab formulation associated with less injection site pain and improved motivation for treatment. Mod Rheumatol 2019; 29(6): 949-53.
[http://dx.doi.org/10.1080/14397595.2018.1520426] [PMID: 30183438]
[25]
Muñoz NH, Rosado AA, Muniesa BH, Lázaro CB, Román AF, Alonso AP. 4CPS-155 Comparative study for evaluation of the pain, ease of use and preference between two adalimumab administration devices: study adap2017. Eur J Hosp Pharm 2018; 25 (Suppl. 1): A114-5.
[http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.246]
[26]
Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther 2016; 3(2): 257-70.
[http://dx.doi.org/10.1007/s40744-016-0041-3] [PMID: 27747583]
[27]
Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet 2015; 386(9993): 541-51.
[http://dx.doi.org/10.1016/S0140-6736(15)60125-8] [PMID: 26072109]
[28]
Krishnan E, Zhang N, Wang H. P497 Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studies. J Crohn’s Colitis 2018; 12 (Suppl. 1): S357-57.
[http://dx.doi.org/10.1093/ecco-jcc/jjx180.624]
[29]
Weinblatt ME, Schiff M, Valente R, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013; 65(1): 28-38.
[http://dx.doi.org/10.1002/art.37711] [PMID: 23169319]
[30]
Burmester GR, Weinblatt ME, Mcinnes IB, Porter D, Barbarash O, Vatutin M. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2012; 72(9): 1445-52.
[http://dx.doi.org/10.1136/annrheumdis-2012-202450] [PMID: 23234647]
[31]
Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013; 72(6): 863-9.
[http://dx.doi.org/10.1136/annrheumdis-2012-201601] [PMID: 22730366]
[32]
Genovese MC, Silverman GJ, Emery P, et al. Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in a heterogeneous rheumatoid arthritis population: Results from a randomized, placebo-controlled, phase 3 trial (FLEX-O). J Clin Rheumatol 2015; 21(5): 231-8.
[http://dx.doi.org/10.1097/RHU.0000000000000276] [PMID: 26203826]
[33]
Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol 2016; 175(2): 273-86.
[http://dx.doi.org/10.1111/bjd.14493] [PMID: 26914406]
[34]
Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: A placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011; 9(8): 670-678.e3.
[http://dx.doi.org/10.1016/j.cgh.2011.04.031] [PMID: 21642014]
[35]
Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: Reshaping the healthcare environment. RMD Open 2019; 5(1): e000900.
[http://dx.doi.org/10.1136/rmdopen-2019-000900] [PMID: 31245050]
[36]
Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60(8): 2272-83.
[http://dx.doi.org/10.1002/art.24638] [PMID: 19644849]
[37]
Shi GH, Pisupati K, Parker JG, et al. Subcutaneous injection site pain of formulation matrices. Pharm Res 2021; 38(5): 779-93.
[http://dx.doi.org/10.1007/s11095-021-03047-3] [PMID: 33942212]
[38]
Eaton M, Que Z, Zhang J, et al. Multi-electrode array of sensory neurons as an in vitro platform to identify the nociceptive response to pharmaceutical buffer systems of injectable biologics. Pharm Res 2021; 38(7): 1179-86.
[http://dx.doi.org/10.1007/s11095-021-03075-z] [PMID: 34244893]
[39]
Yang YL, Lai TW. Citric acid in drug formulations causes pain by potentiating acid-sensing ion channel 1. J Neurosci 2021; 41(21): 4596-606.
[http://dx.doi.org/10.1523/JNEUROSCI.2087-20.2021] [PMID: 33888605]
[40]
Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: Literature review of factors influencing pain sensation at the injection site. Adv Ther 2019; 36(11): 2986-96.
[http://dx.doi.org/10.1007/s12325-019-01101-6] [PMID: 31587143]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy